Stay updated with breaking news from Nasdaq Bcli. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.26 and traded as high as $2.40. Brainstorm Cell Therapeutics shares last traded at $2.32, with a volume of 301,181 shares changing […]
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 2,870,000 shares, a decline of 9.2% from the April 30th total of 3,160,000 shares. Approximately 9.5% of the company’s stock are short sold. […]
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Friday. Separately, Maxim Group increased their target price on Brainstorm Cell Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, […]
StockNews.com downgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) from a hold rating to a sell rating in a report issued on Friday morning. Separately, Maxim Group boosted their price target on Brainstorm Cell Therapeutics from $5.00 to $10.00 and gave the company a buy rating in a report on Friday, March 31st. […]
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 2,930,000 shares, a decrease of 5.5% from the March 31st total of 3,100,000 shares. Currently, 10.4% of the company’s stock are sold short. Based on an […]